SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001685071-19-000029
Filing Date
2019-11-12
Accepted
2019-11-12 06:05:25
Documents
66
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q dova-20190930.htm   iXBRL 10-Q 1289116
2 EXHIBIT 31.1 dovaq32019ex311.htm EX-31.1 17200
3 EXHIBIT 31.2 dovaq32019ex312.htm EX-31.2 17189
4 EXHIBIT 32.1 dovaq32019ex321.htm EX-32.1 10947
  Complete submission text file 0001685071-19-000029.txt   5743658

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dova-20190930.xsd EX-101.SCH 46560
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dova-20190930_cal.xml EX-101.CAL 63563
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dova-20190930_def.xml EX-101.DEF 258891
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dova-20190930_lab.xml EX-101.LAB 577332
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dova-20190930_pre.xml EX-101.PRE 365606
18 EXTRACTED XBRL INSTANCE DOCUMENT dova-20190930_htm.xml XML 814914
Mailing Address 240 LEIGH FARM ROAD DURHAM NC 27707
Business Address 240 LEIGH FARM ROAD DURHAM NC 27707 919-806-4487
Dova Pharmaceuticals Inc. (Filer) CIK: 0001685071 (see all company filings)

IRS No.: 813858961 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38135 | Film No.: 191205627
SIC: 2834 Pharmaceutical Preparations